title: Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells.
abstract: OBJECTIVE
  To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells.
  
  
  METHODS
  The assignment included blank control, h-R3 alone, DDP alone, 5-FU alone, h-R3 combined with DDP, and h-R3 combined with 5-FU. The cell proliferation in each group was measured by MMT method 48 h post dose. The effect on the cell cycle was determined by flow cytometry, and the effect on cell apoptosis was determined by flow cytometry and TUNEL test 48 h post dose.
  
  
  RESULTS
  The inhibitory effect of h-R3 on the proliferation of EC1 cells was weak. The maximum inhibition rate was 10.10 ± 0.58% 48 h post dose, and the difference in the inhibition rate between the h-R3 with chemotherapeutic agents and the chemotherapeutic agent alone was not statistically significant (p > 0.05). Flow cytometry demonstrated no obvious change in the EC1 cells after h-R3 treatment (p > 0.05). Flow cytometry and TUNEL test demonstrated that the difference in the apoptosis rate between h-R3 combined with chemotherapeutic agents and blank control was not statistically significant (p > 0.05).
  
  
  CONCLUSIONS
  h-R3 had no significant effect on human ESCC EC1 cells in vitro, with or without the combination of chemotherapeutic agents.
authors.affiliation: The First Affiliated Hospital of Xinxiang Medical University, Weihui City, Xinxiang, China. sunny8441_cn@sina.com.
authors.forename: Y-H
authors.initials: YH
authors.lastname: Ji
authors.forename: X-Y
authors.initials: XY
authors.lastname: Yang
authors.forename: J-Q
authors.initials: JQ
authors.lastname: Wu
authors.forename: X-Q
authors.initials: XQ
authors.lastname: Huo
authors.forename: W-W
authors.initials: WW
authors.lastname: Li
authors.forename: G-J
authors.initials: GJ
authors.lastname: Li
authors.forename: Y-L
authors.initials: YL
authors.lastname: Mu
authors.forename: P
authors.initials: P
authors.lastname: Lu
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002945:Cisplatin / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C501466:nimotuzumab; D002945:Cisplatin; D005472:Fluorouracil